GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (OTCPK:LOBEF) » Definitions » Institutional Ownership

Lobe Sciences (Lobe Sciences) Institutional Ownership : 0.31% (As of Jun. 10, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Lobe Sciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lobe Sciences's institutional ownership is 0.31%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lobe Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lobe Sciences's Float Percentage Of Total Shares Outstanding is 0.00%.


Lobe Sciences Institutional Ownership Historical Data

The historical data trend for Lobe Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Institutional Ownership Chart

Lobe Sciences Historical Data

The historical data trend for Lobe Sciences can be seen below:

2021-03-31 2021-04-30 2021-05-31 2021-06-30 2021-07-31
Institutional Ownership 2.20 2.27 2.06 0.90 0.31

Lobe Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Lobe Sciences (Lobe Sciences) Business Description

Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.